PK and Safety of CC-90001 in Healthy Japanese and Caucasian Subjects

Phase 1, randomised, open-label trial of CC-90001 in idiopathic pulmonary fibrosis (IPF) and Nonalcoholic steatohepatitis (NASH) (3 cohorts), sponsored by Celgene Corporation. Primary endpoints: Area Under the Curve from time zero to last measurable concentration, Area Under the Curve from time zero to infinity and 5 more. Started Apr 2019; status: completed.